chart update, page-132

KC, why not focus on Oxy C patch for Ph2 as originally planned?
Why the shift to Oxy M, and others? Surely this has added to delays in Oxy C, capital allocated to Oxy C used for new projects.
POH will not have sufficient funds to complete a Ph3 if they go down this path as originally intended.
Why is a Ph2 necessary?

Suds good questions. I refer you to the last Pain ann. You will notice that with Esra deposed Harry has reset the POH commercial compass. Harry wants a Pain Portfolio that addresses a wide range of indications and therefore greatly derisks the clinical program going forward. If both Topical OxyC and Systemic OxyM get up then we have a monster commercial deal. If one trips over we still have another to get a blockbuster deal across the line. The Profile for OxyM is such that it is a more powerful opioid than OxyC and POH can see you dont need 2 drugs doing the same job in the one pain portfolio ( well thats my takeout). Meanwhile OxyC has proven in last trial to be an outstanding candidate for treatment of topical pain for which the market is currently $6-7 Billion ( compares to $3.5 Bill for OxyC systemic). The reason to conduct a Phase 2 is to establish data that a potential licensee can feel comfortable in doing a deal, It is pointless doing a massive and very expensive Phase 3 ( for which POH did admittedly raise $27 Mill at the last CR) when Big Pharma will want to do its own Phase 3 to ensure safe passsage thru the FDA. So POH actually has more than enough funds to do several Phase 2 trials at say $600,000 a pop c/f many millions for an unecessary Phase 3.

Neura Theraputic is driving this commercial path so we are in good hands imho.